[
  {
    "ts": "2026-02-13T02:07:28+00:00",
    "headline": "Vertex Pharmaceuticals Q4 Earnings Call Highlights",
    "summary": "Vertex Pharmaceuticals (NASDAQ:VRTX) management emphasized revenue growth, expanding product diversification, and multiple late-stage pipeline milestones while reviewing fourth-quarter and full-year 2025 results on its earnings call. Executives highlighted continued strength in cystic fibrosis (CF),",
    "url": "https://www.marketbeat.com/instant-alerts/vertex-pharmaceuticals-q4-earnings-call-highlights-2026-02-12/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "a2440f9d-16b1-3da8-9c59-3446d548e6a3",
      "content": {
        "id": "a2440f9d-16b1-3da8-9c59-3446d548e6a3",
        "contentType": "STORY",
        "title": "Vertex Pharmaceuticals Q4 Earnings Call Highlights",
        "description": "",
        "summary": "Vertex Pharmaceuticals (NASDAQ:VRTX) management emphasized revenue growth, expanding product diversification, and multiple late-stage pipeline milestones while reviewing fourth-quarter and full-year 2025 results on its earnings call. Executives highlighted continued strength in cystic fibrosis (CF),",
        "pubDate": "2026-02-13T02:07:28Z",
        "displayTime": "2026-02-13T02:07:28Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/2b24107d7189be99d174df28e69c0745",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "Vertex Pharmaceuticals logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_R3e5J4xXhGqswXyjpPPAA--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/2b24107d7189be99d174df28e69c0745.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/B1sm63HzQpEVAehsaVnbbQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/2b24107d7189be99d174df28e69c0745.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/instant-alerts/vertex-pharmaceuticals-q4-earnings-call-highlights-2026-02-12/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-q4-earnings-call-020728764.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "RPRX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T05:05:06+00:00",
    "headline": "Vertex Pharmaceuticals Inc (VRTX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...",
    "summary": "Vertex Pharmaceuticals Inc (VRTX) reports a 10% revenue increase in Q4 2025, driven by successful product launches and strategic pipeline advancements.",
    "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-inc-vrtx-q4-050506194.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "578cedd8-fe88-3d41-a06a-946f5e7a0ad6",
      "content": {
        "id": "578cedd8-fe88-3d41-a06a-946f5e7a0ad6",
        "contentType": "STORY",
        "title": "Vertex Pharmaceuticals Inc (VRTX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...",
        "description": "",
        "summary": "Vertex Pharmaceuticals Inc (VRTX) reports a 10% revenue increase in Q4 2025, driven by successful product launches and strategic pipeline advancements.",
        "pubDate": "2026-02-13T05:05:06Z",
        "displayTime": "2026-02-13T05:05:06Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-inc-vrtx-q4-050506194.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-inc-vrtx-q4-050506194.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T09:19:47+00:00",
    "headline": "Vertex Expands Autoimmune Pipeline As Investors Weigh Valuation And Growth Potential",
    "summary": "Vertex Pharmaceuticals received FDA orphan drug designation for povetacicept in myasthenia gravis. The company announced an alliance with WuXi Biologics to develop a trispecific T-cell engager for B-cell mediated autoimmune diseases. Both updates relate to Vertex expanding its rare disease and autoimmune portfolio beyond cystic fibrosis. Vertex Pharmaceuticals, NasdaqGS:VRTX, is drawing fresh attention as it adds new rare disease and autoimmune assets alongside its established cystic...",
    "url": "https://finance.yahoo.com/news/vertex-expands-autoimmune-pipeline-investors-091947626.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "48ffa8ba-0ed5-3421-bc57-40751c0f4df4",
      "content": {
        "id": "48ffa8ba-0ed5-3421-bc57-40751c0f4df4",
        "contentType": "STORY",
        "title": "Vertex Expands Autoimmune Pipeline As Investors Weigh Valuation And Growth Potential",
        "description": "",
        "summary": "Vertex Pharmaceuticals received FDA orphan drug designation for povetacicept in myasthenia gravis. The company announced an alliance with WuXi Biologics to develop a trispecific T-cell engager for B-cell mediated autoimmune diseases. Both updates relate to Vertex expanding its rare disease and autoimmune portfolio beyond cystic fibrosis. Vertex Pharmaceuticals, NasdaqGS:VRTX, is drawing fresh attention as it adds new rare disease and autoimmune assets alongside its established cystic...",
        "pubDate": "2026-02-13T09:19:47Z",
        "displayTime": "2026-02-13T09:19:47Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ihFoSuY9PLXURl2kI_sV.w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bIz6sh0rX4c7ACsVP8z51w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-expands-autoimmune-pipeline-investors-091947626.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-expands-autoimmune-pipeline-investors-091947626.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "WXIBF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]